Source comparison
Selank Amidate vs Thymosin Alpha-1: Research Application Comparison
Primary Mechanism GABAergic receptor modulation; upregulates GABA-A receptor subunit expression in hippocampus and prefrontal cortex T-cell maturation signalling via TLR2 binding; enhances IL-2 and IFN-gamma production in antigen-presenting cells Non-overlappi
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GABAergic receptor modulation; upregulates GABA-A receptor subunit expression in hippocampus and prefrontal cortex
- T-cell maturation signalling via TLR2 binding; enhances IL-2 and IFN-gamma production in antigen-presenting cells
- Non-overlapping: one targets neurotransmission, the other targets immune differentiation
- Half-Life Post-Administration
- 15–25 minutes (unmodified tuftsin); extended to 4–6 hours through Pro-Gly-Pro-Gly modification
- 2–3 hours in circulation; cellular effects persist 24–48 hours through downstream cytokine signalling
- Selank requires less frequent dosing in behavioural studies; Thymosin effects outlast serum presence
- Post-Reconstitution Stability
- 28 days refrigerated (2–8°C) without measurable degradation
- 72 hours refrigerated; requires −20°C freezing for longer storage to prevent proteolytic cleavage
- Selank offers greater protocol flexibility; Thymosin demands immediate use or aliquoting
- Typical Research Dosage Range
- 50–300 mcg/kg in rodent behavioural studies; intranasal administration common in human trials
- 0.8–1.6 mg twice weekly in immunotherapy research; subcutaneous injection standard route
- Selank doses scale with body weight; Thymosin uses fixed dosing based on immune response thresholds
- Primary Study Endpoints
- Anxiety-like behaviour (elevated plus maze, open field test), cognitive performance (Morris water maze), neurotransmitter levels
- T-cell subset counts (CD4+, CD8+), cytokine concentrations (IL-2, IFN-gamma), viral titre reduction
- Completely different measurement systems. Behavioural vs immunological assays
- Cost Per Study (Estimated)
- $180–$320 for 30-day rodent protocol (n=10 animals, 200 mcg/kg daily dosing)
- $420–$680 for 8-week immunotherapy protocol (n=10 animals, 1.6 mg twice weekly dosing)
- Thymosin approximately 2× more expensive per animal; reflects longer synthesis and lower stability
- This table is based on published dosing protocols from peer-reviewed studies and commercial supplier pricing as of 2026. Research applications are non-overlapping. Selection depends entirely on whether your study targets neurochemical or immunological systems.